Show simple item record

2019-12-05Zeitschriftenartikel DOI: 10.25646/6639
The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis
dc.contributor.authorAyobami, Olaniyi
dc.contributor.authorWillrich, Niklas
dc.contributor.authorHarder, Thomas
dc.contributor.authorOkeke, Iruka N.
dc.contributor.authorEckmanns, Tim
dc.contributor.authorMarkwart, Robby
dc.date.accessioned2020-04-06T07:26:10Z
dc.date.available2020-04-06T07:26:10Z
dc.date.issued2019-12-05none
dc.identifier.other10.1080/22221751.2019.1698273
dc.identifier.urihttp://edoc.rki.de/176904/6594
dc.description.abstractDue to therapeutic challenges, hospital-acquired infections (HAIs) caused by Acinetobacter baumannii (HA-AB), particularly carbapenem-resistant strains (HA-CRAB) pose a serious health threat to patients worldwide. This systematic review sought to summarize recent data on the incidence and prevalence of HA-AB and HA-CRAB infections in the WHO-defined regions of Europe (EUR), Eastern Mediterranean (EMR) and Africa (AFR). A comprehensive literature search was performed using MEDLINE, EMBASE and GMI databases (01/2014-02/2019). Random-effects meta-analyses were performed to determine the pooled incidence of HA-AB and HA-CRAB infections as well as the proportions of A. baumannii among all HAIs. 24 studies from 3,340 records were included in this review (EUR: 16, EMR: 6, AFR: 2). The pooled estimates of incidence and incidence density of HA-AB infection in intensive care units (ICUs) were 56.5 (95% CI 33.9-92.8) cases per 1,000 patients and 4.4 (95% CI 2.9-6.6) cases per 1,000 patient days, respectively. Five studies conducted at a hospital-wide level or in specialized clinical departments/wards (ICU + non-ICU patients) showed HA-AB incidences between 0.85 and 5.6 cases per 1,000 patients. For carbapenem-resistant A. baumannii infections in ICUs, the pooled incidence and incidence density were 41.7 (95% CI 21.6-78.7) cases per 1,000 patients and 2.1 (95% CI 1.2-3.7) cases per 1,000 patient days, respectively. In ICUs, A. baumannii and carbapenem-resistant A. baumannii strains accounted for 20.9% (95% CI 16.5-26.2%) and 13.6% (95% CI 9.7-18.7%) of all HAIs, respectively. Our study highlights the persistent clinical significance of hospital-acquired A. baumannii infections in the studied WHO regions, particularly in ICUs.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectAcinetobacter baumanniieng
dc.subjecthospital-acquired infectionseng
dc.subjecthealthcare-acquired infectionseng
dc.subjectnosocomial infectionseng
dc.subjectcarbapenem resistanceeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleThe incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysisnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6594-5
dc.identifier.doihttp://dx.doi.org/10.25646/6639
dc.type.versionpublishedVersionnone
local.edoc.container-titleEmerging Microbes & Infectionsnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.tandfonline.com/doi/full/10.1080/22221751.2019.1698273?scroll=top&needAccess=truenone
local.edoc.container-publisher-nameTaylor & Francisnone
local.edoc.container-volume8none
local.edoc.container-issue1none
local.edoc.container-year2019none
local.edoc.container-firstpage1747none
local.edoc.container-lastpage1759none
local.edoc.rki-departmentInfektionsepidemiologienone
dc.description.versionPeer Reviewednone

Show simple item record